

Special Issue

Molecular Mechanisms of Myeloid Cell Differentiation and Resistance to Anti-Tumor Immunity

Message from the Guest Editor

Immunotherapies have revolutionized the treatment of solid tumors over the past decade. However, during tumor progression, tumors implement profound immunosuppression within the tumor microenvironment (TME), leading to resistance to immunotherapies and recurring tumor disease. Chronic cancer inflammation over-activates the immune system, leading to a dramatic expansion and the recruitment of myeloid progenitors that fail to mature into functional myeloid effector cells, thus leading to an imbalance of inflammation and anti-inflammation. The editorial aims to (1) define the molecular, epigenetic, and metabolic networks implicated in persistent myelopoiesis observed in cancer patients (2) discuss the impact of dysfunctional myeloid differentiation on clinical outcomes (3) explore new biomarkers and therapeutic targets in order to restore the differentiation of myeloid progenitors and myeloid cells towards an effector phenotype, thus increasing host antitumor immunity. Restoring the profound alterations in myelopoiesis may help to overcome resistance to immunotherapy in patients with cold tumors, where myeloid cells are key players in mediating immune evasion.

Guest Editor

Dr. Laura Strauss
GenVivo, 475 Huntington Dr, San Marino, CA 91108, USA

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/203022

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).